Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Genomics: Clinical Implementation » Guardant Health, Bristol-Myers Squibb to Deploy Liquid Biopsies in Clinical Trials

Guardant Health, Bristol-Myers Squibb to Deploy Liquid Biopsies in Clinical Trials

Nov 16, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Guardant Health said today that it is working with Bristol-Myers Squibb to develop the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.

Redwood City, California-based Guardant has struck similar partnerships with AstraZeneca, Merck, Merck KGaA, and Pfizer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

New Prototype Test

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

Cell Studies on SARS-CoV-2 Spike Variant, Host Transcriptomes, Glioma-Infiltrating T Cells

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

What's Popular?

In Sequencing

  1. Adaptive Biotechnologies, LabCorp Expand Collaboration

  2. AnchorDx Closes $40M Series C Financing Round

  3. German Medical Center to Report Polygenic Risk Scores as Part of Clinical Whole-Genome Testing

    Premium

  4. NeoGenomics Q4 Revenue Grows 18 Percent, CEO to Retire

  5. Researchers Aim to Improve Lynch Syndrome Testing With Genetic-Epigenetic Combination Method

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.